Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14067482 | 0.92 | ALDH1A1 (0.38) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4901376 | 0.90 | ALDH1A1 (0.39) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4901163 | 0.90 | THRB (0.37) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4904758 | 0.90 | THRB (0.37) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL5540785 | 0.89 | TSHR (0.38) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4898051 | 0.89 | TSHR (0.36) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL14067449 | 0.89 | ALDH1A1 (0.38) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4903178 | 0.89 | ALDH1A1 (0.35) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL16021064 | 0.88 | TSHR (0.38) | TSHRTHRBALDH1A1KDM4EPOLB | |
| SCHEMBL4908683 | 0.88 | GRM5 (0.36) | TSHRTHRBALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | TSHR 4605/4885THRB 3610/4885ALDH1A1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.